Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$13.92 -2.0%	$14.74	$11.51 ▼ $21.87	$2.43B	0.55	102,585 shs	66,078 shs
HRMY Harmony Biosciences	$35.65 +4.7%	$31.38	$26.47 ▼ $41.61	$2.05B	0.82	588,814 shs	958,561 shs
PRTA Prothena	$7.61 +2.4%	$10.95	$6.92 ▼ $25.42	$409.62M	0.11	569,167 shs	1.42 million shs
SAGE Sage Therapeutics	$6.75 +2.9%	$7.50	$4.62 ▼ $13.47	$410.79M	0.2	1.22 million shs	706,487 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	0.00%	-4.93%	+3.94%	+6.26%	-34.44%
HRMY Harmony Biosciences	0.00%	+12.30%	+16.73%	-10.37%	+12.97%
PRTA Prothena	0.00%	-12.59%	-27.30%	-47.19%	-65.18%
SAGE Sage Therapeutics	0.00%	-10.14%	-8.38%	-9.64%	-44.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCM HUTCHMED	2.1049 of 5 stars	3.0	2.0	0.0	2.6	0.0	1.9
HRMY Harmony Biosciences	4.9149 of 5 stars	4.5	3.0	0.0	3.9	3.3	4.4
PRTA Prothena	3.2248 of 5 stars	4.4	2.0	0.0	2.2	1.7	1.3
SAGE Sage Therapeutics	4.2945 of 5 stars	4.0	2.0	4.0	1.9	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.00	Hold	$19.00	36.49% Upside
HRMY Harmony Biosciences	3.00	Buy	$52.33	46.80% Upside
PRTA Prothena	2.75	Moderate Buy	$51.71	579.56% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.81	30.56% Upside

Current Analyst Ratings Breakdown

Latest SAGE, HRMY, HCM, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$48.00 ➝ $30.00
5/9/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$80.00 ➝ $78.00
5/9/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/8/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/18/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $44.00
3/11/2025	SAGE Sage Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$5.00
2/27/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$630.20M	3.85	$0.57 per share	24.51	$4.27 per share	3.26
HRMY Harmony Biosciences	$744.85M	2.75	$2.66 per share	13.38	$7.97 per share	4.47
PRTA Prothena	$137.94M	2.97	N/A	N/A	$10.46 per share	0.73
SAGE Sage Therapeutics	$47.40M	8.92	N/A	N/A	$7.56 per share	0.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$100.78M	N/A	0.00	9.53	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.90	11.46	0.47	17.98%	23.16%	14.24%	N/A
PRTA Prothena	-$147.03M	-$2.08	N/A	N/A	N/A	-90.50%	-22.67%	-19.68%	N/A
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-971.50%	-68.18%	-60.84%	7/30/2025 (Estimated)

Latest SAGE, HRMY, HCM, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
2/25/2025	Q4 2024	HRMY Harmony Biosciences	$0.74	$0.85	+$0.11	$0.85	$201.25 million	$201.30 million
2/20/2025	Q4 2024	PRTA Prothena	-$1.02	-$1.08	-$0.06	-$1.08	$7.53 million	$2.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.07	2.81	2.68
HRMY Harmony Biosciences	0.28	3.24	3.20
PRTA Prothena	N/A	11.52	11.52
SAGE Sage Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
HRMY Harmony Biosciences	86.23%
PRTA Prothena	97.08%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
HRMY Harmony Biosciences	23.60%
PRTA Prothena	9.20%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,760	174.32 million	168.04 million	Not Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
PRTA Prothena	130	53.83 million	38.64 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	58.10 million	Optionable

SAGE, HRMY, HCM, and PRTA Headlines

Recent News About These Companies

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation

May 11 at 10:00 AM | accessnewswire.com

J.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

May 10 at 4:18 AM | theglobeandmail.com

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation

May 8, 2025 | accessnewswire.com

Major Depressive Disorder Pipeline Report 2025: Comprehensive Insights of 75+ Companies and Drugs Under Clinical Assessment

May 8, 2025 | finance.yahoo.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out

May 6, 2025 | accessnewswire.com

Trinity Life Sciences Announces Winners of TGaS Advisors Best of Benchmark Awards for Operational Excellence in Pharma Industry

May 6, 2025 | finance.yahoo.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation

May 4, 2025 | accessnewswire.com

HC Wainwright Issues Optimistic Estimate for SAGE Earnings

May 4, 2025 | marketbeat.com

Wedbush Equities Analysts Raise Earnings Estimates for SAGE

May 4, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Invests $1.17 Million in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 4, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by StockNews.com

May 4, 2025 | americanbankingnews.com

Wedbush Research Analysts Lift Earnings Estimates for SAGE

May 4, 2025 | americanbankingnews.com

Q2 EPS Estimate for Sage Therapeutics Raised by Analyst

May 4, 2025 | americanbankingnews.com

Brokers Issue Forecasts for SAGE Q1 Earnings

May 3, 2025 | marketbeat.com

Caligan Partners LP Makes New Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 3, 2025 | marketbeat.com

PDT Partners LLC Buys 63,804 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

May 3, 2025 | marketbeat.com

Analysts Set Expectations for SAGE Q1 Earnings

May 2, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Estimates By $0.01 EPS

May 1, 2025 | marketbeat.com

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 1, 2025 | accessnewswire.com

Q1 2025 SAGE Therapeutics Inc Earnings Call

May 1, 2025 | finance.yahoo.com

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...

May 1, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAGE, HRMY, HCM, and PRTA Company Descriptions

HUTCHMED NASDAQ:HCM

$13.92 -0.29 (-2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$14.10 +0.18 (+1.26%)

As of 07:21 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Harmony Biosciences NASDAQ:HRMY

$35.65 +1.60 (+4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$35.16 -0.48 (-1.36%)

As of 04:38 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Prothena NASDAQ:PRTA

$7.61 +0.18 (+2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$7.76 +0.15 (+2.04%)

As of 07:35 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Sage Therapeutics NASDAQ:SAGE

$6.75 +0.19 (+2.90%)

Closing price 04:00 PM Eastern

Extended Trading

$6.85 +0.10 (+1.54%)

As of 06:00 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time